Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gyre Therapeutics ( (GYRE) ) has issued an announcement.
On May 15, 2026, Gyre Therapeutics planned to present a detailed corporate and scientific update at a conference in Shanghai, highlighting its expanded pipeline and recently announced acquisition of protein degrader specialist Cullgen. The company emphasized its strategy to leverage cost-efficient Chinese R&D and validation capabilities, together with its existing manufacturing and commercial infrastructure, to accelerate development of degrader- and drug-antibody conjugate-based therapies for fibrosis, inflammatory diseases and solid tumors, a move that could strengthen its competitive position and broaden its commercial reach.
Management outlined key value drivers including a balanced portfolio from preclinical candidates like CDK2/Cyclin E and TYK2/JAK1 degraders to marketed assets for lung and liver fibrosis, underpinned by cross-border leadership teams in the U.S. and China. By integrating Cullgen’s protein degrader platform with Gyre’s China innovation engine and global clinical operations, the combined entity aims to advance risk-mitigated products toward larger markets, positioning itself as a more formidable player in next-generation oncology and immunology therapeutics.
The most recent analyst rating on (GYRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.
Spark’s Take on GYRE Stock
According to Spark, TipRanks’ AI Analyst, GYRE is a Neutral.
The score is primarily supported by strong financial fundamentals (rapid revenue growth, very high gross margins, and low leverage) and positive corporate catalysts (F351 priority review acceptance and Cullgen acquisition). These positives are tempered by weak technical momentum (below key moving averages, negative MACD) and loss-making valuation signals (negative P/E).
To see Spark’s full report on GYRE stock, click here.
More about Gyre Therapeutics
Gyre Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on developing therapies for fibrosis, inflammatory diseases and cancer, with a pipeline spanning discovery-stage assets to marketed products such as pirfenidone and hydronidone. The Nasdaq-listed group operates through a global footprint anchored by corporate headquarters in San Diego and extensive discovery, manufacturing, clinical development and commercialization operations in Shanghai and Beijing, employing about 740 staff across research, manufacturing, sales and general administration.
Average Trading Volume: 97,147
Technical Sentiment Signal: Sell
Current Market Cap: $708.1M
For an in-depth examination of GYRE stock, go to TipRanks’ Overview page.